文献速递皮肤感染

蜂窝织炎与丹毒的抗生素治疗评估:系统综述与Meta分析

Assessment of Antibiotic Treatment of Cellulitis and Erysipelas: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2019-01-01

该系统综述与Meta分析纳入43项随机临床试验共5999例可评估参与者,年龄1月至96岁。总体未发现任一抗生素优于其他,抗MRSA药物无额外优势,静脉给药和超过5天疗程均缺乏证据支持。仅低质量证据支持最适药物、给药途径和疗程,未来试验需标准化结局。

要点

  • 未发现任一抗生素优于其他,抗MRSA药物无额外获益。
  • 静脉给药优于口服、疗程超过5天均缺乏证据支持。
  • 现有证据质量低,需标准化结局与疗程设计未来试验。

核心结论

  • 仅低质量证据支持蜂窝织炎最适抗生素、给药途径和疗程,未来试验需标准化结局。

研究设计与样本

  • 纳入比较不同抗生素、给药途径和疗程的随机临床试验,共43项研究5999例可评估参与者,年龄1月至96岁。

主要发现

  • 仅15项研究(35%)以蜂窝织炎为主要诊断,其他研究中蜂窝织炎患者比例中位数(四分位距)为29.7%(22.9%-50.3%)。
  • 总体未发现任一抗生素优于其他,抗MRSA药物无额外优势。
  • 静脉给药优于口服、疗程超过5天均缺乏证据支持。

关键数值与推荐

  • 主要结局为治疗结束时治愈、改善、恢复或无/减轻症状的患者比例,次要结局为任何不良事件。
  • 采用Cochrane协作网标准方法,二分类结局计算风险比及95%CI,采用GRADE方法评估证据质量。

临床怎么用

  • 临床选择抗生素、给药途径和疗程时应认识到现有证据质量低,缺乏明确优势方案。

局限性

  • 仅低质量证据支持最适药物、给药途径和疗程。
  • 仅35%研究以蜂窝织炎为主要诊断,其他研究蜂窝织炎比例中位数29.7%。
  • 未来试验需标准化结局,包括严重度评分、剂量和疗程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The optimum antibiotic treatment for cellulitis and erysipelas lacks consensus. The available trial data do not demonstrate the superiority of any agent, and data are limited on the most appropriate route of administration or duration of therapy. OBJECTIVE: To assess the efficacy and safety of antibiotic therapy for non-surgically acquired cellulitis. DATA SOURCES: The following databases were searched to June 28, 2016: Cochrane Central Register of Controlled Trials (2016, issue 5), Medline (from 1946), Embase (from 1974), and Latin American and Caribbean Health Sciences Information System (LILACS) (from 1982). In addition, 5 trials databases and the reference lists of included studies were searched. Further searches of PubMed and Google Scholar were undertaken from June 28, 2016, to December 31, 2018. STUDY SELECTION: Randomized clinical trials comparing different antibiotics, routes of administration, and treatment durations were included. DATA EXTRACTION AND SYNTHESIS: For data collection and analysis, the standard methodological procedures of the Cochrane Collaboration were used. For dichotomous outcomes, the risk ratio and its 95% CI were calculated. A summary of findings table was created for the primary end points, adopting the GRADE approach to assess the quality of the evidence. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients cured, improved, recovered, or symptom-free or symptom-reduced at the end of treatment, as reported by the trial. The secondary outcome was any adverse event. RESULTS: A total of 43 studies with a total of 5999 evaluable participants, whose age ranged from 1 month to 96 years, were included. Cellulitis was the primary diagnosis in only 15 studies (35%), and in other studies the median (interquartile range) proportion of patients with cellulitis was 29.7% (22.9%-50.3%). Overall, no evidence was found to support the superiority of any 1 antibiotic over another, and antibiotics with activity against methicillin-resistant Staphylococcus aureus did not add an advantage. Use of intravenous antibiotics over oral antibiotics and treatment duration of longer than 5 days were not supported by evidence. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, only low-quality evidence was found for the most appropriate agent, route of administration, and duration of treatment for patients with cellulitis; future trials need to use a standardized set of outcomes, including severity scoring, dosing, and duration of therapy.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Brindle R, Williams OM, Barton E, et al. Assessment of Antibiotic Treatment of Cellulitis and Erysipelas: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019. PMID: 31188407. doi:10.1001/jamadermatol.2019.0884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。